KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) FCF Margin (2016 - 2026)

Acadia Pharmaceuticals has reported FCF Margin over the past 16 years, most recently at 18.57% for Q4 2025.

  • For Q4 2025, FCF Margin fell 3395.0% year-over-year to 18.57%; the TTM value through Dec 2025 reached 9.84%, down 657.0%, while the annual FY2025 figure was 9.81%, 660.0% down from the prior year.
  • FCF Margin for Q4 2025 was 18.57% at Acadia Pharmaceuticals, down from 26.52% in the prior quarter.
  • Over five years, FCF Margin peaked at 36.96% in Q4 2023 and troughed at 66.1% in Q1 2022.
  • A 5-year average of 4.98% and a median of 5.15% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: skyrocketed 5444bps in 2023 and later crashed -3395bps in 2025.
  • Year by year, FCF Margin stood at 17.68% in 2021, then rose by 1bps to 17.48% in 2022, then soared by 311bps to 36.96% in 2023, then crashed by -58bps to 15.38% in 2024, then tumbled by -221bps to 18.57% in 2025.
  • Business Quant data shows FCF Margin for ACAD at 18.57% in Q4 2025, 26.52% in Q3 2025, and 24.17% in Q2 2025.